41.35 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||40.79 x 1000|
|Ask||42.01 x 1200|
|Day's Range||41.16 - 41.47|
|52 Week Range||37.43 - 45.62|
|Beta (3Y Monthly)||0.39|
|PE Ratio (TTM)||21.31|
|Forward Dividend & Yield||1.86 (4.20%)|
|1y Target Est||N/A|
"This opioid crisis has become a fentanyl crisis," the CEO of Opiant Dr. Roger Crystal told Yahoo Finance's Alexis Christoforous. He then goes on to discuss what else the pharmaceutical company is doing to tackle the epidemic.
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
German drugmaker Boehringer Ingelheim reported on Wednesday flat operating income of 3.5 billion euros ($4 billion) for 2018, held back by the costs of integrating the animal medicines business it acquired from Sanofi. Strong revenue gains from Boeringer's diabetes drugs were partly offset by declining revenues for its top-selling inhalable lung drug Spiriva, under pressure from rival drugs. As a result, total group sales fell 3 percent last year to 17.5 billion euros ($19.8 billion), the family-owned group said.
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Sanofi's (EPA:SAN), to help you decide if the stock is worth further research...
The move is a pre-emptive one as the French drugmaker is set to testify before the House Energy and Commerce Committee on the rising prices of insulin later in the day.
Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers - Eli Lilly & Co and Novo Nordisk A/S - will also testify.
Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally ...
At a time when the flu season is typically coming to a close, the Centers for Disease Control and Prevention said this week that the number of cases and related medical visits continue to be elevated. Flu season typically ranges from November to March, with flu-like illness peaking in February, the CDC said. The incidence of patients testing positive for the flu virus influenza A (H1N1), influenza A (H3N2) and influenza B are slightly increased for the most recent three-week period, with influenza A(H3) reported more frequently, according to the federal agency.
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Sanofi's (EPA:SAN) earnings update on 31 December 2018, analyst...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
The Brisbane company next year could have FDA and European approvals for a way to protect people with peanut allergy from accidental exposures. But competitors are numerous.
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.